The Patent Finder

CG Oncology, Inc.

Also on record
Records under this name other than the patents CG Oncology, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.

Back to CG Oncology, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,473,418Pan cancer oncolytic vectors and methods of use thereof
Term ended
Term ended Mar 9, 2025 · USPTO record
Term endedTerm ended Mar 9, 2025USPTO record
US 7,858,083Pan Cancer Oncolytic Vectors and Methods of Use Thereof
Term ended
Ended no later than Mar 9, 2025 · Low confidence
Term endedEnded no later than Mar 9, 2025Low confidence
US 7,459,154Methods and reagents for the enhancement of virus transduction in the bladder epithelium
Term ended
Term ended Sep 15, 2023 · USPTO record
Term endedTerm ended Sep 15, 2023USPTO record
US 7,267,815Methods and reagents for the enhancement of virus transduction in the bladder epithelium
Term ended
Term ended Mar 18, 2023 · USPTO record
Term endedTerm ended Mar 18, 2023USPTO record
US 7,968,333Adenovirus vectors containing cell status-specific response elements and methods of use thereof
Term ended
Term ended Sep 18, 2021 · USPTO record
Term endedTerm ended Sep 18, 2021USPTO record
US 6,692,736Cell-specific adenovirus vectors comprising an internal ribosome entry site
Term ended
Term ended Jul 16, 2021 · USPTO record
Term endedTerm ended Jul 16, 2021USPTO record
US 6,991,935Target cell-specific adenoviral vectors containing E3 and methods of use thereof
Term ended
Term ended Aug 7, 2020 · USPTO record
Term endedTerm ended Aug 7, 2020USPTO record
US 6,495,130Target cell-specific adenoviral vectors containing E3 and methods of use thereof
Term ended
Ended no later than Dec 29, 2019 · USPTO record
Term endedEnded no later than Dec 29, 2019USPTO record
US 7,575,919Adenovirus vectors containing cell status-specific response elements and methods of use thereof
Term ended
Ended no later than Sep 9, 2019 · USPTO record
Term endedEnded no later than Sep 9, 2019USPTO record
US RE42,373Adenovirus vectors containing cell status-specific response elements and methods of use thereof
Term ended
Ended no later than Sep 9, 2019 · USPTO record
Term endedEnded no later than Sep 9, 2019USPTO record
10 of 14 patents shown.
Pro members see all 14.
Pro members: see all 14 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited